BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note published on Monday, Benzinga reports. The brokerage currently has a $12.00 price target on the biotechnology company’s stock.

BCRX has been the subject of a number of other research reports. Royal Bank of Canada reissued an outperform rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, September 25th. StockNews.com started coverage on BioCryst Pharmaceuticals in a research note on Thursday, October 5th. They set a hold rating for the company. Jefferies Financial Group raised shares of BioCryst Pharmaceuticals from a hold rating to a buy rating and set a $11.00 target price on the stock in a research note on Friday, August 4th. HC Wainwright reissued a buy rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, August 4th. Finally, Bank of America upgraded shares of BioCryst Pharmaceuticals from a neutral rating to a buy rating and set a $10.00 price objective on the stock in a research report on Thursday, July 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of Moderate Buy and an average price target of $13.63.

BioCryst Pharmaceuticals Stock Down 1.8 %

BioCryst Pharmaceuticals stock opened at $5.93 on Monday. The firm has a fifty day simple moving average of $6.52 and a two-hundred day simple moving average of $7.24. BioCryst Pharmaceuticals has a twelve month low of $5.21 and a twelve month high of $14.20. The company has a market capitalization of $1.12 billion, a PE ratio of -4.60 and a beta of 1.92.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Fifth Third Bancorp boosted its stake in shares of BioCryst Pharmaceuticals by 17,500.0% during the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,500 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after buying an additional 2,388 shares during the period. Fairfield Bush & CO. bought a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at approximately $34,000. State of Wyoming purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $35,000. Finally, Advisory Services Network LLC raised its position in shares of BioCryst Pharmaceuticals by 46.3% in the 1st quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,500 shares in the last quarter. 91.46% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.